| Abstract: | Background: Severe asthma with fungal sensitivity (SAFS) is a recently described form of asthma that is difficult to treat with conventional inhaled corticosteroids. Antifungal therapies such as itraconazole might be an option. Objective: To discuss the data from a study evaluating efficacy and safety of itraconazole therapy in SAFS. Methods/results: Itraconazole therapy was found to improve quality of life and reduce immune response, with no impact on lung function. Conclusions: Itraconazole may be a promising therapy in SAFS, provided its potential of reducing airway inflammation is further documented. |
